Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ridaifen-B

Known as: RID-B compound 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PyrrolidinesTamoxifen
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Novel Ridaifen-B Structure Analog Induces Apoptosis and Autophagy Depending on Pyrrolidine Side Chain.
Ridaifen (RID)-B is an analog derived from tamoxifen (TAM). TAM has an antitumor effect by acting as an antagonist to estrogen… Expand
2018
2018
The tamoxifen derivative ridaifen‐B is a high affinity selective CB2 receptor inverse agonist exhibiting anti‐inflammatory and anti‐osteoclastogenic effects
&NA; Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2.
Ridaifen B (RID-B) is a tamoxifen derivative that potently inhibits breast tumor growth. RID-B was reported to show anti… Expand
2013
2013
Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement.
Autophagy is a self-proteolysis process in eukaryotic cells that results in the sequestering of intracellular proteins and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2008
2008
Induction of mitochondria‐involved apoptosis in estrogen receptor‐negative cells by a novel tamoxifen derivative, ridaifen‐B
Tamoxifen is an antagonist of estrogen receptor, which is used widely as an estrogen receptor‐positive breast cancer drug that… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE